American heart journal
-
American heart journal · Dec 2003
Randomized Controlled Trial Clinical TrialAcetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Contrast-induced nephropathy (CIN) after coronary angiography is associated with increased morbidity and mortality rates. Preliminary studies with N-acetylcysteine (NAC) have found conflicting results in the prevention of CIN in patients undergoing coronary angiography. This study was designed to evaluate the efficacy and safety of NAC in the prevention of CIN in patients undergoing coronary angiography. ⋯ In patients with reduced renal function undergoing elective coronary angiography, NAC does not reduce the risk of CIN.
-
American heart journal · Dec 2003
Randomized Controlled Trial Clinical TrialA randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes.
The acute benefits of platelet glycoprotein IIb/IIIa inhibitors for non-ST-segment elevation acute coronary syndromes (NSTE ACS) remain unclear. ⋯ In this pilot trial, early administration of eptifibatide in the emergency department did not modulate serologic measurements of infarct size in patients with NSTE ACS.